Skip to content

News & Media

25th February 2025
Elixirgen Therapeutics Publishes Early Results Showing Telomere Elongation in First Gene Therapy Trial for Telomere Biology Disorders
20th February 2025
Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders
13th February 2025
Elixirgen Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EXG-34217 for Treatment of Telomere Biology Disorders
25th September 2024
Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders
7th August 2024
How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?
6th June 2024
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics’ Aki Ko
24th April 2024
Elixirgen Therapeutics’ Innovative Approach to mRNA Therapeutics
28th March 2024
Elixirgen Therapeutics’ Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki Ko
21st March 2024
Developing an mRNA therapy for Duchenne muscular dystrophy
20th March 2024
NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy
Top